MEDIWOUND LTD (MDWD) Stock Price & Overview
NASDAQ:MDWD • IL0011316309
Current stock price
The current stock price of MDWD is 16.63 USD. Today MDWD is up by 0.79%. In the past month the price decreased by -1.07%. In the past year, price decreased by -3.59%.
MDWD Key Statistics
- Market Cap
- 213.696M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -2.10
- Dividend Yield
- N/A
MDWD Stock Performance
MDWD Stock Chart
MDWD Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to MDWD. When comparing the yearly performance of all stocks, MDWD is a bad performer in the overall market: 76.96% of all stocks are doing better.
MDWD Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to MDWD. MDWD may be in some trouble as it scores bad on both profitability and health.
MDWD Earnings
On March 5, 2026 MDWD reported an EPS of -0.56 and a revenue of 1.87M. The company beat EPS expectations (13.08% surprise) and missed revenue expectations (-70.05% surprise).
MDWD Forecast & Estimates
12 analysts have analysed MDWD and the average price target is 30.4 USD. This implies a price increase of 82.78% is expected in the next year compared to the current price of 16.63.
For the next year, analysts expect an EPS growth of -33.65% and a revenue growth 16.75% for MDWD
MDWD Index Membership
MDWD is currently included in the following stock indexes tracked on ChartMill.
MDWD Financial Highlights
Over the last trailing twelve months MDWD reported a non-GAAP Earnings per Share(EPS) of -2.1. The EPS increased by 31.6% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -27.68% | ||
| ROE | -54.73% | ||
| Debt/Equity | 0.19 |
MDWD Ownership
MDWD Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 22.63 | 883.029B | ||
| JNJ | JOHNSON & JOHNSON | 17.91 | 553.619B | ||
| MRK | MERCK & CO. INC. | 11.43 | 269.662B | ||
| PFE | PFIZER INC | 8.81 | 151.879B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.41 | 123.709B | ||
| ZTS | ZOETIS INC | 16.14 | 48.347B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.57 | 28.899B | ||
| VTRS | VIATRIS INC | 6.03 | 17.396B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.39 | 11.171B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 10.626B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 6.109B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.971B | ||
| CORT | CORCEPT THERAPEUTICS INC | 35.54 | 4.948B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About MDWD
Company Profile
MediWound Ltd. is a biopharmaceutical company, which engages in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. Company's portfolio is focused on next-generation protein-based therapies for burn and wound care and tissue repair and includes products such as, NexoBrid, a concentrate of proteolytic enzymes enriched in bromelain, which is an easy to use, topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues. ; EscharEx biological drug candidate for the debridement of chronic and other hard-to-heal wounds; MW005 a topically applied biological drug candidate for the treatment of non-melanoma skin cancers, based on the same API of NexoBrid and EscharEx products, a concentrate of proteolytic enzymes enriched in bromelain.
Company Info
IPO: 2014-03-20
MEDIWOUND LTD
42 Hayarkon Street
YAVNE 8122745 IL
CEO: Sharon Malka
Employees: 121
Phone: 972779714100
MEDIWOUND LTD / MDWD FAQ
What does MDWD do?
MediWound Ltd. is a biopharmaceutical company, which engages in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. Company's portfolio is focused on next-generation protein-based therapies for burn and wound care and tissue repair and includes products such as, NexoBrid, a concentrate of proteolytic enzymes enriched in bromelain, which is an easy to use, topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues. ; EscharEx biological drug candidate for the debridement of chronic and other hard-to-heal wounds; MW005 a topically applied biological drug candidate for the treatment of non-melanoma skin cancers, based on the same API of NexoBrid and EscharEx products, a concentrate of proteolytic enzymes enriched in bromelain.
Can you provide the latest stock price for MEDIWOUND LTD?
The current stock price of MDWD is 16.63 USD. The price increased by 0.79% in the last trading session.
What is the dividend status of MEDIWOUND LTD?
MDWD does not pay a dividend.
How is the ChartMill rating for MEDIWOUND LTD?
MDWD has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the analyst forecast for MDWD stock?
12 analysts have analysed MDWD and the average price target is 30.4 USD. This implies a price increase of 82.78% is expected in the next year compared to the current price of 16.63.
Can you provide the upcoming earnings date for MEDIWOUND LTD?
MEDIWOUND LTD (MDWD) will report earnings on 2026-05-19.